September 13, 2019 / 5:15 AM / a month ago

BRIEF-Roche: Update On Genentech’s Breast Cancer Therapy

Sept 13 (Reuters) - Roche Holding AG:

* GENENTECH’S FIXED DOSE SUBCUTANEOUS COMBINATION OF PERJETA AND HERCEPTIN SHOWED NON-INFERIORITY WHEN COMPARED TO INTRAVENOUS FORMULATIONS FOR PEOPLE WITH HER2-POSITIVE BREAST CANCER

* DATA WILL BE SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD, INCLUDING U.S. FOOD AND DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY Source text: [bit.ly/2lKvy1B] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below